when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog
drugs
Restasis

drug

Restasis

Marketedupdated 3mo ago

by $ABBV AbbVie Inc.

Approved

community read0 votes

🐶 often sniffed alongside

top 6

tagApproval248 co-mentions · 124 sources
drugSANDIMMUNE247 co-mentions · 125 sources
drugCYCLOSPORINE247 co-mentions · 125 sources
drugCequa125 co-mentions · 125 sources
tagSmall Molecule86 co-mentions · 86 sources
tagRecall1 co-mentions · 1 sources

Protein drug with a maximum clinical stage of Approval (across all indications), with 12 approved and 71 investigational indications.

all catalysts(100)

approval · 100

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

$NVS156.24-2.54%

SANDIMMUNE (CYCLOSPORINE) — FDA approval

view all 100 catalysts →

Trials studying Restasis

phase4Efficacy of Vevye Ophthalmic Solution for the Treatment of Meibomian Gland Dysfunctionrecruitingn=48
phase4Comparison of Conjunctival Goblet Cell Density in Dry Eye Patients Treated With Cyclosporine 0.1% Dissolved in Perfluorobutylpentane (Vevye®) or Generic 0.05% Cyclosporine Emulsion for 8 Weeksnot yet recruitingn=60
—Real-World Assessment of VEVYE® for Short-Term Symptom and Sign Improvement of Dry Eye Disease in a Neuro-Ophthalmology Clinic: A 6-Month Prospective Observational Studyrecruitingn=50
phase3Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)terminatedn=164
phase2Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemiarecruitingn=20
phase2Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignanciesrecruitingn=60
phase3Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)completedn=169
phase3A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medicationsrecruitingn=102

more trials →

Patent cliff

source: FDA Orange Book

first barrier falls

Nov 3, 2027

~1.2 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

Apr 1, 2042formulationUS 12059449
Oct 11, 2039method-of-use (U-3627)US 11413323
Nov 20, 2038formulationUS 11154513
Sep 22, 2037formulationUS 10813976
Feb 28, 2037formulationUS 10918694
Feb 28, 2037method-of-use (U-1483)US 11951153
Sep 29, 2036method-of-use (U-3627)US 12496326
Aug 23, 2033formulationUS 10441630
Aug 23, 2033formulationUS 8980839
Aug 23, 2033formulationUS 9937225
Dec 13, 2030formulationUS 86141784.3y
Jun 2, 2029formulationUS 91320712.8y
Nov 3, 2027formulationUS 82985681.2y
Jan 27, 2026method-of-use (U-3560)US 11612658
Jan 27, 2026formulationUS 7973081
Jan 27, 2026formulationUS 8524779
Jan 27, 2026formulationUS 9220694
Jan 27, 2026formulationUS 9956289

FDA exclusivities (2)

Jun 23, 2028ODE-358Orphan Drug (7y)1.8y
May 30, 2026NPNP

News(1)

With $263M, LifeMine unearths a new drug for organ transplants
Led by serial biotech entrepreneur Greg Verdine, the startup mined fungi genomes to find a safer alternative to the drugs widely used to prevent the body from rejecting transplanted organs.
biopharma_dive · 14d ago

brand

Restasis

generic

cyclosporine

MOA

Cyclophilin A modulator

indication

Keratoconjunctivitis Sicca (Dry Eye)

phase

marketed

Data sources

openFDA · ClinicalTrials.gov

last refreshed 8m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?